MedWatch

Allarity keeps streamlining pipeline – sells cancer drug for USD 18m

Biotech company Allarity Therapeutics has divested a drug candidate to US Lantern Pharma, from which the Danish company in-licensed the drug in 2015. The deal may amount to USD 18m.

Photo: Allarity Therapeutics / PR

Danish medical company Allarity Therapeutics has divested the drug Irufulven to US-stocklisted company Lantern Pharma. The total price including an upfront payment and development and regulatory milestone fees may amount to around USD 18m, not including the royalties the company can earn from the sales, according to a Monday press release from the Danish company, which is listed in Sweden.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs